What is HC Wainwright’s Estimate for WINT FY2024 Earnings?

Windtree Therapeutics, Inc. (NASDAQ:WINT) – Research analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Windtree Therapeutics in a report issued on Wednesday, December 4th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($5.66) per share for the year, down from their prior estimate of ($2.38). HC Wainwright has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Windtree Therapeutics’ current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Windtree Therapeutics’ Q4 2024 earnings at ($0.92) EPS and FY2025 earnings at ($2.86) EPS.

Windtree Therapeutics Stock Down 4.7 %

Windtree Therapeutics stock opened at $0.37 on Friday. The firm has a fifty day moving average of $0.81 and a 200-day moving average of $3.73. Windtree Therapeutics has a 52-week low of $0.35 and a 52-week high of $16.74. The firm has a market capitalization of $3.33 million, a P/E ratio of -0.02 and a beta of 0.54.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.